Clinical trial · Observational
Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis
Identification and Validation of Plasma Diagnostic Biomarkers for Multi-Cancer Based on Metabolomics: A Multi-Center Clinical Research and Validation Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this observational study is to comprehensively analyze the metabolites in plasma samples from multi-cancer patients using advanced mass spectrometry detection technology, in conjunction with metabolomics approaches. The goal is to construct a plasma metabolite database for multi-cancer patients. Simultaneously, we will delve into the exploration and validation of a series of metabolic biomarkers for early multi-cancer diagnosis. The objective is to establish a safer, more convenient, and more sensitive early screening method, thereby providing a reliable scientific foundation and critical evidence for improving the early diagnostic process for individuals at high risk of multi-cancer.
Conditions
Conditions (13)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
| Cholangiocarcinoma | Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
| Liver Cancer | Malignant Liver Neoplasm | CURATED_EXACT | 0.92 |
| Lung Cancer | Malignant Lung Neoplasm |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Multi-cancer group
- description
- Patients diagnosed with cancer, including lung cancer，breast cancer，colorectal cancer，thyroid cancer，gastric cancer，cervical cancer，liver cancer，pancreatic cancer，cholangiocarcinoma，prostate cancer，esophageal cancer，ovarian cancer，renal cell carcinoma.
- label
- control group
- description
- Healthy controls
Primary outcomes (1)
- measure
- Plasma metabolite content
- timeFrame
- Before receiving treatment for cancer
- description
- The outcome will be tested by metabolomics detection technology based on mass spectrometry
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Multi-Cancer Group: * Patients with a confirmed diagnosis based on the clinical "gold standard". * Collection of plasma samples prior to treatment. * Availability of complete clinical data. * Control Group: * Individuals with no abnormalities in routine physical examinations and relevant clinical tests. * Age ≥ 45 years. * Availability of complete clinical data. Exclusion Criteria: * Previous reception of anti-tumor treatments (including radiotherapy, chemotherapy, etc.) before blood collection. * Coexistence of other systemic tumors. * Absence of plasma sample collection before treatment. * Pregnancy status. * No clear evidence of histopathological diagnosis (not applicable to the control group based on this criterion). * Patients with severe acute infections. * Patients with severe anemia. * Patients with severe liver or kidney dysfunction. * Patients with autoimmune deficiency diseases. * Patients with Hyperlipidemia. * Patients received contrast agent injection before blood draw. * Patients with psychiatric disorders.
References
Publications (0)
Data not yet available